Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease

Sponsor
Fakultas Kedokteran Universitas Indonesia (Other)
Overall Status
Unknown status
CT.gov ID
NCT04126850
Collaborator
(none)
10
1
8.9
1.1

Study Details

Study Description

Brief Summary

This study aimed to discover the composition on the microbiome in several sites of the human body; and to find out the difference in microbiome composition on ocular fluid, blood, and feces before and after therapy in uveitis patient with history of autoimmune disease (Behcet and Vogt-Koyanagi-Harada) and idiopathic uveitis

Detailed Description

Gut microbiome has been widely studied around the globe, and it is convinced that the gut microbiome plays an essential role in many human diseases. In a published review showed the presence of microbes in blood from a patient who suffered from non-communicable disease. The microbes present in dormant or not-immediately-culturable states as if blood is a 'sterile' environment. It was argued that the difficulty of culturing microbes from the blood was coming from the limited understanding of suitable growth/isolation media for the microbes to be cultured. This limitation can be overcome by the sequenced-based methods for detecting non-proliferating microbes. The presence of microbes in blood also can be observed by ultrastructural (microscopic) methods. Through the microscopic observations, it was witnessing the presence of coccus and bacillus shaped bacteria that present proximity to (Red Blood Cell) RBCs in sample blood patients with Alzheimer's or Parkinson's Disease. The presence of microbes in the places other than their normal location state by term 'atopobiosis'. The presence of microbes in blood suspected as a result of translocation between the gut to the blood.

Therefore, according to the current knowledge of microbiome association and the human diseases, we are eager to conduct a pilot project that gives a comprehensive picture of the association between the microbiome and uveitis disease partially non-infectious and idiopathic uveitis. We will investigate microbiome profiling in the intestinal and extra-intestinal of uveitis patients before and after treatment to see whether any alteration of microbial abundance at two distinct clinical conditions partially in uveitis patients with history of autoimmune disease (Behcet and Vogt-Koyanagi-Harada) and idiopathic uveitis. Another objective of this study is to explore any pathogenic microorganism that present in uveitis patients samples conducted by a sequenced-based method.

Study Design

Study Type:
Observational
Anticipated Enrollment :
10 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Pilot Project: The Amplicon and Metatranscriptomic Next-generation Sequencing of Samples From Intra and Extra-intestinal Microbiome in Non-infectious Uveitis Patients to Decipher Possibility Uveitis Pathogenesis
Anticipated Study Start Date :
Nov 1, 2019
Anticipated Primary Completion Date :
Jul 30, 2020
Anticipated Study Completion Date :
Jul 30, 2020

Outcome Measures

Primary Outcome Measures

  1. Differential abundant taxonomic groups bacterial [0, 6 weeks]

    The primer used in this amplicon study is targeted to 16S rRNA gene region V3-V4 to detect bacterial diversity in the samples. The sequencing will be generated by Illumina according to standard protocol. Prior filter is conducted using Prinseq-lite, then chimeric sequences remove using Usearch61 and left over the high quality reads. The (operational taxonomic unit) OTU is picked using bioinformatic tool (Quantitative Insights Into Microbial Ecology - QIIME). Taxonomic classification for de novo OTUs clustering will be generated using open source software package for bioinformatics data processing. Shanon diversity, Simpson index will be examined for calculating alpha diversity. And then we will do identification of differential abundant taxonomic groups. And do analysis correlation network between bacterial genera among two clinical condition (before and after received oral steroid) relatively to health control.

Secondary Outcome Measures

  1. Detection pathogenic microorganism in samples [0, 6 weeks]

    In this study we are going to use IDseq Portal, a novel bioinformatics platform that designed for detection of microbes from metagenomic data. This analysis will be applied in all types samples (stool, blood, and aqueous humor). We expect to find any specific microbiome (bacterial/fungal/virus) signature in samples patient uveitis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • New patient registered at Cipto Mangunkusumo Hospital since November 2019

  • Patient diagnosed with non-infectious uveitis (with Behcet, VKH history)

  • Patient idiopathic uveitis (proven to have negative result by available etiological uveitis work-ups)

  • Minimum age: 18 years old

  • Experience active inflammation in the past 180 days and or during patient registration following Standard Uveitis Nomenclature (SUN) guidelines, in at least:

  • equal and or more than 2+ anterior chamber cells

  • equal and or more than 2+ vitreous haze and/or

  • active retinal/choroidal lesions

Exclusion Criteria:
  • patients had taken probiotics supplement or antibiotics 3 months before sample collection

  • or who experience prolonged diarrhea or constipation

  • or undergone gastrointestinal surgery

  • having any form of malignancy

  • having a systemic disease such as hypertension, obesity, inflammatory bowel disease, or diabetes.

  • Disagree to sign informed consent

  • Uveitis is proven to be an infectious origin

  • Pregnant patient

  • Loss to follow up patient

Healthy volunteers are recruited for this study after giving consent with the following inclusion criteria:

  • age: 18-50 years old (Man/Woman)

  • having no health complaints or symptoms

  • not in any long term medications

  • having no history of allergy

  • willing to cooperate in the study

  • state of complete physical, mental and social well being

Contacts and Locations

Locations

Site City State Country Postal Code
1 RSUPN dr. Cipto Mangunkusumo (Cipto Mangunkusumo Hospital) Jakarta Pusat Jakarta Indonesia 10320

Sponsors and Collaborators

  • Fakultas Kedokteran Universitas Indonesia

Investigators

  • Principal Investigator: Ratna Sitompul, Professor, RSUPN dr. Cipto Mangunkusumo Hospital (RSCM)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ratna Sitompul, Prof. Dr. dr. Ratna Sitompul, SpM(K), Fakultas Kedokteran Universitas Indonesia
ClinicalTrials.gov Identifier:
NCT04126850
Other Study ID Numbers:
  • 19-05-0624
First Posted:
Oct 15, 2019
Last Update Posted:
Oct 17, 2019
Last Verified:
Oct 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ratna Sitompul, Prof. Dr. dr. Ratna Sitompul, SpM(K), Fakultas Kedokteran Universitas Indonesia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 17, 2019